Literature DB >> 24233839

Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.

Hsin-Jung Lee1, Yung-Ming Jeng, Yu-Ling Chen, Ling Chung, Ray-Hwang Yuan.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common fatal cancers worldwide. Other than the sorafenib treatment, no effective systemic therapy has been available thus far. Most targets in molecularly targeted therapy for cancer are receptor tyrosine kinases (RTKs). Therefore, identifying activated RTKs in HCC is critical for developing new molecularly targeted therapies. Using a phospho-RTK array, we found that Axl is one of the most frequently activated RTKs in liver cancer cell lines. The knockdown of Axl by RNA interference significantly reduced cell migration and invasion in the HCC cell lines HA22T and Mahlavu. Stimulation of HCC cell lines by Axl ligand growth arrest-specific 6 (Gas6) enhanced cell migration and invasion. The Gas6/Axl pathway enhanced the expression of the epithelial-mesenchymal transition-inducing transcription factor Slug, which is essential for the invasion-promoting activity of Axl. Treating HCC cells with the Axl inhibitor bosutinib suppressed Slug expression and decreased the invasiveness of HCC cell lines. These findings indicate that Gas6/Axl regulates tumor invasion through the transcriptional activation of Slug.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24233839     DOI: 10.1093/carcin/bgt372

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  56 in total

1.  Gas6 expression is reduced in advanced breast cancers.

Authors:  Ayman M Ibrahim; Zane Gray; Angelica M Gomes; Leann Myers; Fariba Behbod; Heather L Machado
Journal:  NPJ Precis Oncol       Date:  2020-04-24

Review 2.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  Tyro3 carboxyl terminal region confers stability and contains the autophosphorylation sites.

Authors:  Hanshuang Shao; Douglas Lauffenburger; Alan Wells
Journal:  Biochem Biophys Res Commun       Date:  2017-06-28       Impact factor: 3.575

4.  The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.

Authors:  Anna Orlova; Heidi A Neubauer; Richard Moriggl
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

5.  Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.

Authors:  Kinga Pénzes; Christine Baumann; István Szabadkai; László Orfi; György Kéri; Axel Ullrich; Robert Torka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

6.  The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Authors:  Jane Antony; Elisa Zanini; Zoe Kelly; Tuan Zea Tan; Evdoxia Karali; Mohammad Alomary; Youngrock Jung; Katherine Nixon; Paula Cunnea; Christina Fotopoulou; Andrew Paterson; Sushmita Roy-Nawathe; Gordon B Mills; Ruby Yun-Ju Huang; Jean Paul Thiery; Hani Gabra; Chiara Recchi
Journal:  EMBO Rep       Date:  2018-06-15       Impact factor: 8.807

7.  Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma.

Authors:  Martin Golkowski; Ho-Tak Lau; Marina Chan; Heidi Kenerson; Venkata Narayana Vidadala; Anna Shoemaker; Dustin J Maly; Raymond S Yeung; Taranjit S Gujral; Shao-En Ong
Journal:  Cell Syst       Date:  2020-08-04       Impact factor: 10.304

8.  A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Thomas C C Yau; Riccardo Lencioni; Wattana Sukeepaisarnjaroen; Yee Chao; Chia-Jui Yen; Wirote Lausoontornsiri; Pei-Jer Chen; Theeranun Sanpajit; Aaron Camp; Donna S Cox; Robert C Gagnon; Yuan Liu; Kristen E Raffensperger; Diptee A Kulkarni; Howard Kallender; Lone Harild Ottesen; Ronnie T P Poon; Donald P Bottaro
Journal:  Clin Cancer Res       Date:  2016-11-07       Impact factor: 12.531

Review 9.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Junjiang Fu
Journal:  Tumour Biol       Date:  2014-06-02

Review 10.  Does Axl have potential as a therapeutic target in pancreatic cancer?

Authors:  Wenting Du; Rolf A Brekken
Journal:  Expert Opin Ther Targets       Date:  2018-10-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.